# Biotech Daily Digest — 2026-02-02

**26 items from 5 sources**

## Summary by Source

- Endpoints News: 2 items
- Fierce Biotech: 7 items
- MHRA – News: 1 item
- Regeneron Press Releases: 1 item
- arXiv q-bio: 15 items


## Endpoints News

- **[SanegeneBio licenses RNAi candidate to Genentech for $200M upfront](https://endpoints.news/sanegenebio-licenses-rnai-candidate-to-genentech-for-200m-upfront/)**  
  _Mon, 02 Feb 2026 14:35:38 +0000_  
  Genentech will pick up an RNAi candidate from SanegeneBio, a China and US biotech fresh off a $110 million Series B.

 The Roche unit will pay $200 million upfront for the global ...

- **[Sanofi’s venglustat succeeds in Phase 3 Gaucher trial but fails separate study in Fabry disease](https://endpoints.news/sanofis-venglustat-succeeds-in-phase-3-gaucher-trial-but-fails-separate-study-in-fabry-disease/)**  
  _Mon, 02 Feb 2026 12:12:25 +0000_  
  Sanofi’s investigational drug, with a track record of mixed results in the clinic, has passed a Phase 3 trial in Gaucher disease, but flunked a separate late-stage study in Fabry disease.


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/medtech/optellum-tapped-nhs-ai-powered-lung-cancer-diagnostic-initiative" hreflang="en">Optellum tapped by NHS for AI-powered lung cancer diagnostic initiative</a>](https://www.fiercebiotech.com/medtech/optellum-tapped-nhs-ai-powered-lung-cancer-diagnostic-initiative)**  
  _Feb 2, 2026 8:31am_  
  Optellum, a 2016 spinout from the University of Oxford, has been tapped by the U.K.’s National Health Service to use its AI-powered lung cancer diagnostic as part of an effort by the agency to more accurately detect the disease earlier and reduce invasive procedures.

- **[<a href="https://www.fiercebiotech.com/biotech/roches-return-rna-continues-17b-deal-sanegene-program" hreflang="en">Roche's return to RNA continues with $1.7B deal for Sanegene program </a>](https://www.fiercebiotech.com/biotech/roches-return-rna-continues-17b-deal-sanegene-program)**  
  _Feb 2, 2026 7:59am_  
  Roche is continuing its return to the RNAi space by paying $200 million for the worldwide license to one of SanegeneBio’s programs.

- **[<a href="https://www.fiercebiotech.com/biotech/early-stage-investor-sante-ventures-gins-330m-spread-across-biotech-medtech-and-digital" hreflang="en">Early-stage investor Santé Ventures gins up $330M to spread across biotech, medtech and digital health</a>](https://www.fiercebiotech.com/biotech/early-stage-investor-sante-ventures-gins-330m-spread-across-biotech-medtech-and-digital)**  
  _Jan 30, 2026 3:38pm_  
  As biotech and other sectors of the life sciences industry espouse cautious optimism for a stabler financing environment in 2026, the steady influx of new funds in the space suggests things are trending in a better direction so far. The latest firm to top up its venture capital coffers is Austin, Texas-based Santé Ven…

- **[<a href="https://www.fiercebiotech.com/medtech/month-after-alcons-failed-merger-bid-staar-surgical-searches-next-ceo-appoints-interim" hreflang="en">A month after Alcon deal fell through, Staar Surgical searches for next CEO and names interim leaders</a>](https://www.fiercebiotech.com/medtech/month-after-alcons-failed-merger-bid-staar-surgical-searches-next-ceo-appoints-interim)**  
  _Feb 2, 2026 7:21am_  
  Staar Surgical has endured a whirlwind start to the New Year with a rejected takeover deal and the loss of its CEO less than a year into the job. Now, the company is forging ahead with new execs at the top as it looks for a future leader to help right the ship.

- **[<a href="https://www.fiercebiotech.com/medtech/astrazeneca-study-finds-22-genes-tied-chronic-disease-risk-after-epstein-barr-infection" hreflang="en">AstraZeneca study finds 22 genes tied to chronic disease risk after Epstein-Barr infection</a>](https://www.fiercebiotech.com/medtech/astrazeneca-study-finds-22-genes-tied-chronic-disease-risk-after-epstein-barr-infection)**  
  _Feb 2, 2026 3:11am_  
  Nine in 10 people worldwide have been infected with Epstein-Barr virus. But only a small number will go on to develop serious illnesses that have been linked to the virus, such as lupus, chronic lung disease and lymphoma.

- **[<a href="https://www.fiercebiotech.com/biotech/sanofis-troubled-gcs-inhibitor-fails-phase-3-fabry-trial-wins-gaucher-disease" hreflang="en">Sanofi's troubled GCS inhibitor fails phase 3 Fabry trial but scores in Gaucher disease</a>](https://www.fiercebiotech.com/biotech/sanofis-troubled-gcs-inhibitor-fails-phase-3-fabry-trial-wins-gaucher-disease)**  
  _Feb 2, 2026 5:48am_  
  Sanofi’s pipeline features a number of once-hyped candidates that are struggling to deliver in the clinic, and the latest mixed phase 3 data from venglustat continue this trend.

- **[<a href="https://www.fiercebiotech.com/biotech/formation-bios-china-shopping-spree-continues-500m-biobucks-autoimmune-pact" hreflang="en">Formation Bio's China shopping spree continues with $500M biobucks autoimmune pact</a>](https://www.fiercebiotech.com/biotech/formation-bios-china-shopping-spree-continues-500m-biobucks-autoimmune-pact)**  
  _Jan 29, 2026 12:20pm_  
  AI-fueled Formation Bio has inked another licensing deal for a China asset, this time picking up an oral small molecule designed to treat autoimmune disease in a deal worth up to $500 million biobucks.


## MHRA – News

- **[Mila to Millions: A New Era of Individualized Medicines](https://www.gov.uk/government/news/mila-to-millions-a-new-era-of-individualized-medicines)**  
  _2026-02-02T12:22:59Z_  
  By Julia Vitarello


## Regeneron Press Releases

- **[EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases](https://investor.regeneron.com/news-releases/news-release-details/eylea-hdr-aflibercept-injection-8-mg-presentations-angiogenesis)**  
  _Mon, 02 Feb 2026 07:00:00 -0500_  
  New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated with monthly dosing TARRYTOWN, N.Y., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals,


## arXiv q-bio

- **[Emergent spatial organization of competing species under environmental stress and cooperation](https://arxiv.org/abs/2601.22177)**  
  _Mon, 02 Feb 2026 00:00:00 -0500_  
  arXiv:2601.22177v1 Announce Type: new 
Abstract: Understanding how species persist under interacting stressors is a central challenge in ecology. We develop a spatially explicit reaction-diffusion framework to investigate competing species in landscapes shaped by climate variability, pollution, resource heterogeneity,…

- **[Structural properties of distance-bounded phylogenetic reconciliation](https://arxiv.org/abs/2601.22193)**  
  _Mon, 02 Feb 2026 00:00:00 -0500_  
  arXiv:2601.22193v1 Announce Type: new 
Abstract: Phylogenetic reconciliation seeks to explain host-symbiont co-evolution by mapping parasite trees onto host trees through events such as cospeciation, duplication, host switching, and loss. Finding an optimal reconciliation that ensures time feasibility is computational…

- **[Beyond Conditional Computation: Retrieval-Augmented Genomic Foundation Models with Gengram](https://arxiv.org/abs/2601.22203)**  
  _Mon, 02 Feb 2026 00:00:00 -0500_  
  arXiv:2601.22203v1 Announce Type: new 
Abstract: Current genomic foundation models (GFMs) rely on extensive neural computation to implicitly approximate conserved biological motifs from single-nucleotide inputs. We propose Gengram, a conditional memory module that introduces an explicit and highly efficient lookup pri…

- **[Minimal-Action Discrete Schr\"odinger Bridge Matching for Peptide Sequence Design](https://arxiv.org/abs/2601.22408)**  
  _Mon, 02 Feb 2026 00:00:00 -0500_  
  arXiv:2601.22408v1 Announce Type: new 
Abstract: Generative modeling of peptide sequences requires navigating a discrete and highly constrained space in which many intermediate states are chemically implausible or unstable. Existing discrete diffusion and flow-based methods rely on reversing fixed corruption processes…

- **[Effects of multi-phase control mechanism on fibroblast dynamics: A segmented mathematical modeling approach](https://arxiv.org/abs/2601.22613)**  
  _Mon, 02 Feb 2026 00:00:00 -0500_  
  arXiv:2601.22613v1 Announce Type: new 
Abstract: Cell size is a fundamental determinant of cellular physiology, influencing processes such as growth, division, and function. In this study, we develop a segmented mathematical framework to investigate how different control mechanisms operating across multiple phases of…

- **[Epigenetic state inheritance drivers drug-tolerant persister-induced resistance in solid tumors: A stochastic agent-based model](https://arxiv.org/abs/2601.22619)**  
  _Mon, 02 Feb 2026 00:00:00 -0500_  
  arXiv:2601.22619v1 Announce Type: new 
Abstract: The efficacy of anti-cancer therapies is severely limited by the emergence of drug resistance. While genetic drivers are well-characterized, growing evidence suggests that non-genetic mechanisms, particularly those involving drug-tolerant persisters (DTPs), play a pivot…

- **[Classification of SARS-CoV-2 Variants through The Epistatical Circos Plots with Convolutional Neural Networks](https://arxiv.org/abs/2601.22866)**  
  _Mon, 02 Feb 2026 00:00:00 -0500_  
  arXiv:2601.22866v1 Announce Type: new 
Abstract: The COVID-19 pandemic has profoundly affected global health, driven by the remarkable transmissibility and mutational adaptability of the SARS-CoV-2 virus. Five major variants of concern, Alpha, Beta, Gamma, Delta, and Omicron, have been identified. By August 2022, over…

- **[Microbiome association diversity reflects proximity to the edge of instability](https://arxiv.org/abs/2601.22918)**  
  _Mon, 02 Feb 2026 00:00:00 -0500_  
  arXiv:2601.22918v1 Announce Type: new 
Abstract: Recent advances in metagenomics have revealed macroecological patterns or "laws" describing robust statistical regularities across microbial communities. Stochastic logistic models (SLMs), which treat species as independent -- akin to ideal gases in physics -- and incor…

- **[How adaptation to food resources and death rates shape oscillatory dynamics in a microbial population](https://arxiv.org/abs/2601.22967)**  
  _Mon, 02 Feb 2026 00:00:00 -0500_  
  arXiv:2601.22967v1 Announce Type: new 
Abstract: Microbes constantly interact with their environment by depleting and transforming food sources. Theoretical studies have mainly focused on Lotka-Volterra models, which do not account for food source dynamics. In contrast, consumer-resource models, which consider food so…

- **[The Where and How of Touch: A Review of Tactile Localization Research](https://arxiv.org/abs/2601.23023)**  
  _Mon, 02 Feb 2026 00:00:00 -0500_  
  arXiv:2601.23023v1 Announce Type: new 
Abstract: Tactile localization is the seemingly simple ability to 'tell' where a touch has occurred. However, how this ability is assessed, and what conclusions are drawn from experiments, depends on the theoretical ideas that inspire the research. Here, we review both theoretica…

- **[Unveiling Scaling Behaviors in Molecular Language Models: Effects of Model Size, Data, and Representation](https://arxiv.org/abs/2601.22757)**  
  _Mon, 02 Feb 2026 00:00:00 -0500_  
  arXiv:2601.22757v1 Announce Type: cross 
Abstract: Molecular generative models, often employing GPT-style language modeling on molecular string representations, have shown promising capabilities when scaled to large datasets and model sizes. However, it remains unclear and subject to debate whether these models adhere…

- **[Omni-fMRI: A Universal Atlas-Free fMRI Foundation Model](https://arxiv.org/abs/2601.23090)**  
  _Mon, 02 Feb 2026 00:00:00 -0500_  
  arXiv:2601.23090v1 Announce Type: cross 
Abstract: Self-supervised fMRI foundation models have shown promising transfer performance, yet most rely on predefined region-level parcellations that discard fine-grained voxel information and introduce atlas-dependent biases. We propose Omni-fMRI, an atlas-free foundation mo…

- **[Dynamics of attractor transitions in Boolean networks under noise](https://arxiv.org/abs/2506.15581)**  
  _Mon, 02 Feb 2026 00:00:00 -0500_  
  arXiv:2506.15581v2 Announce Type: replace 
Abstract: Biological systems operate under persistent noise, which can alter system states and induce transitions between attractors. Here, we study the attractor dynamics of Boolean networks focusing on the transitions between attractors induced by noise. By computing transi…

- **[InstructPLM-mu: 1-Hour Fine-Tuning of ESM2 Beats ESM3 in Protein Mutation Predictions](https://arxiv.org/abs/2510.03370)**  
  _Mon, 02 Feb 2026 00:00:00 -0500_  
  arXiv:2510.03370v3 Announce Type: replace 
Abstract: Multimodal protein language models deliver strong performance on mutation-effect prediction, but training such models from scratch demands substantial computational resources. In this paper, we propose a fine-tuning framework called InstructPLM-mu and try to answer…

- **[Large Deviations of Mean-Field Jump-Markov Processes on Structured Sparse Disordered Graphs](https://arxiv.org/abs/2410.13682)**  
  _Mon, 02 Feb 2026 00:00:00 -0500_  
  arXiv:2410.13682v2 Announce Type: replace-cross 
Abstract: We prove a Large Deviation Principle for {\color{blue} jump-Markov } Processes on sparse large disordered network with disordered connectivity. The network is embedded in a geometric space, with the probability of a connection a (scaled) function of the spatia…
